Novo Nordisk stock plummets 12.4% after weight-loss pill Ozempic fails Alzheimer's trials — All you need to know

Shares of Danish pharma major Novo Nordisk's plummeted a record 12.4% on 24 November — it's lowest since July 2021, after the company's popular weight-loss pill Ozempic failed trials for Alzheimer's treatment, Bloomberg reported.Novo Nordisk has discontinued its planned one-year extension for the pair of studies that were testing the drug's effectiveness in slowing the progression of Alzheimer's disease, it added.The two trials, with 3,500 participants with mild Alzheimer’s disease, had a 75% probability of ...